A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia

International Clinical Psychopharmacology

Volumn 23, Issue 4, 2008, Pages 223-227

  Doruk, Ali ^a   Uzun, Özcan ^a   Özşahin, Aytekin ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Clozapine; Efficacy; Extract of ginkgo biloba; Treatment resistant schizophrenia

Indexed keywords

CLOZAPINE; GINKGO BILOBA EXTRACT; PLACEBO; NEUROLEPTIC AGENT; PLANT EXTRACT;

ADULT; AGED; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; GINKGO BILOBA; HUMAN; MALE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT INDICATION; COMPARATIVE STUDY; DRUG COMBINATION; PHYTOTHERAPY;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG THERAPY, COMBINATION; FEMALE; GINKGO BILOBA; HUMANS; MALE; PHYTOTHERAPY; PLANT EXTRACTS; SCHIZOPHRENIA;

EID: 54049124138     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3282fcff2f     Document Type: Article

References (31)

1. Andreasen NC (1981). The Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa.
2. Andreasen NC (1984). The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa.
3. Atmaca M, Tezcan E, Kuloglu M, Ustundag B, Kirtas O (2005). The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia. Psychiatry Clin Neurosci 59:652-656.
4. Cadet JL, Kahler LA (1994). Free radical mechanisms in schizophrenia and tardive dyskinesia. Neurosci Biobehav Rev 18:457-467.
5. Corapcioglu A, Aydemir O, Yildiz M, Esen A, Koroglu E (1999). Structured Clinical Interview for DSM IV (SCID), Turkish version. Ankara: Hekimler Yayin Birligi.
6. Curson DA, Patel M, Liddle PF, Barnes TRE (1988). Psychiatric morbidity of a long stay hospital population with chronic schizophrenia and implications for future community care. Br Med J 297:819-822.
7. Dakhale G, Khanzode S, Khanzode S, Saoji A, Khobragade L, Turankar A (2004). Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 49:205-209.
8. First MB, Spitzer RL, Williams JBW (1997). Structured Clinical Interview for DSM-IV (SCID). Washington DC: American Psychiatric Association.
9. Graham DG (1978). Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinines. Mol Pharmacol 14: 633-643.
10. Graham DG (1979). On the origin and significance of neuromelanin. Arch Pathol Lab Med 103:359-362.
11. Horrobin DF, Glen AI, Vaddadi K (1994). The membrane hypothesis of schizophrenia. Schizophr Res 13:195-207.
12. Kane JM (1992). Clinical efficacy of clozapine in treatment refractory schizophrenia: an overview. Br J Psychiatry 160 (Suppl 17):4145.
13. Kane JM, Honigfeld G, Singer J, Meltzer HY (Clozaril Collaborative Study Group) (1988). Clozapine for treatment resistant schizophrenia: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
14. Knable MB (2002). Extract of ginkgo biloba added to haloperidol was effective for positive symptoms in refractory schizophrenia. Evid Based Ment Health 5:90.
15. Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N (2002). Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 20:171-175.
16. Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, et al. (2004). Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry 65:551-556.
17. Lukoff D, Nuechterlein KH, Ventura J (1986). Manual for the Expanded Brief Psychiatric Rating Scale. Schizophr Bull 12:594-602.
18. Luo HC, Shen YC, Meng FQ (1997). Therapeutic effect of shuxuening combining neuroleptics for treatment of chronic schizophrenia-a double blind study. Zhongguo Zhong Xi Yi Jie He Za Zhi 17:139-142 (Abstract).
19. Lyne J, Kelly BD, O'Connor WT (2004). Schizophrenia: a review of neuropharmacology. Ir J Med Sci 173:155-159.
20. Mahadik SP, Mukherjee S (1996). Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 19:1-17.
21. Mahadik SP, Evans D, Lal H (2001). Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 25:463-493.
22. Maitra I, Marcocci L, Droy-Lefaix MT, Packer L (1995). Peroxyl radical scavenging activity of ginkgo biloba extract EGb 761. Biochem Pharmacol 49: 1649-1655.
23. McKenna DJ, Jones K, Hughes K (2001). Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applications. Altern Ther Health Med 7: 70-86.
24. Reddy R, Mahadik SP, Murthy JN (1991). Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol Psychiatry 30:409-412.
25. Shah AA, Sharma P,Vohora SB (2003). Ginkgo biloba normalises stress-elevated alterations in brain catecholamines, serotonin and plasma corticosterone levels. Eur Neuropsychopharmacol 13:321-325.
26. Wahlbeck K, Cheine M, Essali A, Adams C (1999). Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 156:990-999.
27. Yao JK, Reddy RD, van Kammen DP (2001). Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15:287-310.
28. Zhang XY, Zhou DF, Zhang PY, Wu GY, Su JM, Cao LY (2001a). A double-blind, placebo-controlled trial of extract of ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry 62: 878-883.
29. Zhang XY, Zhou DF, Su JM, Zhang PY (2001b). The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. J Clin Psychopharmacol 21:85-88.
30. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY (2003). Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Res 117:85-88.
31. Zhou D, Zhang X, Su J, Nan Z, Cui Y, Liu J, et al. (1999). The effects of classic antipsychotic haloperidol plus the extract of ginkgo biloba on superoxide dismutase in patients with chronic refractory schizophrenia. Chin Med J 112:1093-1096.